Lv72
3310 积分 2023-01-10 加入
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment
23小时前
待确认
Cancers des voies biliaires : nouvelles approches thérapeutiques médicales orientées par les données moléculaires
5天前
已关闭
Autoimmune Disorders of the Liver and Biliary Tract
12天前
已完结
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
14天前
已完结
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
14天前
已完结
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial
14天前
已完结
Immunotherapy for hepatocellular carcinoma
15天前
已完结
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
17天前
已完结
Immunotherapy advances in uro-genital malignancies
18天前
已完结
Development of Chinese innovative drugs in the USA
28天前
已完结
皖公网安备34019202002308
